• Japanese
  • Korean
  • Chinese
Cover Image

Immunology Partnering Terms and Agreements

The ‘Immunology Partnering Terms and Agreements’ report provides comprehensive understanding and unprecedented access to the immunology partnering deals and agreements entered into by the worlds leading healthcare companies.

Description

The report provides a detailed understanding and analysis of how and why companies enter immunology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors immunology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual immunology deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in immunology dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading immunology deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of immunology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all immunology deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all immunology partnering deals signed and announced since 2009. The chapter is organized by specific immunology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all immunology partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in immunology partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of immunology technologies and products.

Benefits

‘Immunology Partnering Terms and Agreements’ provides the reader with the following key benefits:

  • In-depth understanding of immunology deal trends since 2009
  • Access immunology deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between immunology partner companies
  • Comprehensive access to over 1,000 links to actual immunology deals entered into by the world's biopharma companies
  • Indepth review of immunology deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner immunology opportunities
  • Uncover companies actively partnering immunology opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in immunology dealmaking

  • 2.1. Introduction
  • 2.2. Immunology partnering over the years
  • 2.3. Bigpharma immunology dealmaking activity
  • 2.4. Bigpharma not active in immunology
  • 2.5. Immunology partnering by deal type
  • 2.6. Immunology partnering by industry sector
  • 2.7. Immunology partnering by stage of development
  • 2.8. Immunology partnering by technology type
  • 2.9. Immunology partnering by immunology indication
  • 2.10. Average deal terms for immunology
    • 2.10.1. Immunology headline values
    • 2.10.2. Immunology upfront payments
    • 2.10.3. Immunology milestone payments
    • 2.10.4. Immunology royalty rates

Chapter 3 - Leading immunology deals

  • 3.1. Introduction
  • 3.2. Top immunology deals by value
  • 3.3. Top immunology deals involving bigpharma

Chapter 4 - Bigpharma immunology deals

  • 4.1. Introduction
  • 4.2. How to use bigpharma partnering deals
  • 4.3. Bigpharma immunology partnering company profiles
    • Abbott
    • Allergan
    • Amgen
    • Aspen Pharmacare
    • Astellas
    • AstraZeneca
    • Baxter International
    • Bayer
    • Biogen Idec
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Celgene
    • CSL
    • Daiichi Sankyo
    • Dainippon Sumitomo
    • Eisai
    • Eli Lilly
    • Forest Laboratories
    • Gilead Sciences
    • GlaxoSmithKline
    • Grifols
    • Johnson & Johnson
    • Lundbeck
    • Merck & Co
    • Merck KGaA
    • Mitsubishi Tanabe
    • Novartis
    • Novo Nordisk
    • Pfizer
    • Purdue
    • Roche
    • Sanofi
    • Servier
    • Shionogi
    • Takeda
    • Teva
    • Valeant
    • Watson

Chapter 5 - Immunology partnering contracts directory

  • 5.1. Introduction
  • 5.2. By deal type
    • Asset purchase
    • Assignment
    • Bigpharma outlicensing
    • Co-development
    • Collaborative R&D
    • Co-market
    • Contract service
    • Co-promotion
    • Cross-licensing
    • Development
    • Distribution
    • Equity purchase
    • Joint venture
    • Licensing
    • Litigation
    • Loan
    • Manufacturing
    • Marketing
    • Option
    • Promotion
    • Research
    • Settlement
    • Sub-license
    • Supply
    • Termination
  • 5.3. By stage of development
    • Discovery
    • Formulation
    • Marketed
    • Phase I
    • Phase II
    • Phase III
    • Preclinical
    • Regulatory
  • 5.4. By technology type
    • Antibodies
    • Assays
    • Biological compounds
    • Cell therapy
    • Devices
    • Discovery tools
    • Drug delivery
    • Enabling technology
    • Equipment
    • Facilities
    • Genomics
    • In vitro models
    • Natural product
    • Oligonucleotide
    • Orphan drug
    • Packaging
    • Peptides
    • Processes
    • Proteomics
    • Recombinant DNA
    • RNA therapeutics
    • Screening
    • Small molecules
    • Stem cells
    • Vaccines

Chapter 6 - Immunology dealmaking by indication

  • 6.1. Introduction
  • 6.2. Deals by therapeutic indication
    • Immunology
    • AIDS
    • Allergy
    • Anaphylactic shock
    • Graft versus host disease
    • Inflammation
    • Systemic lupus erythematosus
    • Scleroderma

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Directory of immunology deals by company A-Z 2009-2014
  • Appendix 2 - Directory of immunology deals by deal type 2009-2014
  • Appendix 3 - Directory of immunology deals by stage of development 2009-2014
  • Appendix 4 - Directory of immunology deals by technology type 2009-2014
  • Appendix 5 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports
  • Order Form - Therapy Reports

Table of Figures

  • Figure 1: Immunology partnering since 2009
  • Figure 2: Bigpharma - top 50 - immunology deals 2009 to 2012
  • Figure 3: Bigpharma immunology deal frequency - 2009 to 2012
  • Figure 4: Inactive bigpharma in immunology 2009-2014
  • Figure 5: Immunology partnering by deal type since 2009
  • Figure 6: Immunology partnering by industry sector since 2009
  • Figure 7: Immunology partnering by stage of development since 2009
  • Figure 8: Immunology partnering by technology type since 2009
  • Figure 9: Immunology partnering by immunology target since 2009
  • Figure 10: Immunology deals with a headline value
  • Figure 11: Immunology deal headline value distribution, US$million - discovery stage
  • Figure 12: Immunology deal headline value distribution, US$million - preclinical stage
  • Figure 13: Immunology deal headline value distribution, US$million - phase I stage
  • Figure 14: Immunology deal headline value distribution, US$million - phase II stage
  • Figure 15: Immunology deal headline value distribution, US$million - phase III stage
  • Figure 16: Immunology deal headline value distribution, US$million - regulatory stage
  • Figure 17: Immunology deal headline value distribution, US$million - marketed stage
  • Figure 18: Summary median headline value by stage of development, 2009-2014
  • Figure 19 Immunology deals with upfront payment values
  • Figure 20: Immunology deal upfront payment distribution, US$million - discovery stage
  • Figure 21: Immunology deal upfront payment distribution, US$million - preclinical stage
  • Figure 22: Immunology deal upfront payment distribution, US$million - phase I stage
  • Figure 23: Immunology deal upfront payment distribution, US$million - phase II stage
  • Figure 24: Immunology deal upfront payment distribution, US$million - phase III stage
  • Figure 25: Immunology deal upfront payment distribution, US$million - regulatory stage
  • Figure 26: Immunology deal upfront payment distribution, US$million - marketed stage
  • Figure 27: Summary median upfront payments by stage of development, 2009-2014
  • Figure 28: Immunology deals with milestone payments
  • Figure 29: Immunology deal milestone distribution, US$million - discovery stage
  • Figure 30: Immunology deal milestone distribution, US$million - preclinical stage
  • Figure 31: Immunology deal milestone distribution, US$million - phase I stage
  • Figure 32: Immunology deal milestone distribution, US$million - phase II stage
  • Figure 33: Immunology deal milestone distribution, US$million - phase III stage
  • Figure 34: Immunology deal milestone distribution, US$million - regulatory stage
  • Figure 35: Immunology deal milestone distribution, US$million - marketed stage
  • Figure 36: Immunology deals with royalty rates, %
  • Figure 37: Immunology deal royalty rate distribution, US$million - discovery stage
  • Figure 38: Immunology deal royalty rate distribution, US$million - preclinical stage
  • Figure 39: Immunology deal royalty rate distribution, US$million - phase I stage
  • Figure 40: Immunology deal royalty rate distribution, US$million - phase II stage
  • Figure 41: Immunology deal royalty rate distribution, US$million - phase III stage
  • Figure 42: Immunology deal royalty rate distribution, US$million - regulatory stage
  • Figure 44: Summary median royalty rate by stage of development, 2009-2014
  • Figure 45: Top immunology deals by value since 2009
  • Figure 46: Top immunology deals signed by bigpharma value since 2009
  • Figure 47: Online partnering resources
Show More
Pricing
Get Notified
Email me when related reports are published